USPTO Grants Sanovas Notice of Allowance for Nested Balloon Catheter

Sanovas Inc. announced that it received a Notice of Allowance for its nested balloon catheter for localized drug delivery from the United States Patent and Trademark Office (USPTO). Like other new systems that offer localized, targeted drug delivery, Sanovas’ nested balloon catheter could help overcome systemic toxicity, a major hurdle in treating chemotherapy.

As quoted in the press release:

The patent covers a unique minimally invasive system and method for delivering diagnostic and therapeutic agents to small diameter anatomy in the lungs and throughout the body.

The nested balloon catheter patent, written by Sanovas founders Erhan Gunday and Larry Gerrans, will protect an integral part of the company’s NanoVas™ drug delivery technology.

Erhan Gunday, Sanovas’ chief technology officer and co-founder, commented:

This patent is an important milestone in the protection of the company’s proprietary drug delivery technologies. With more than 45 patents and patents pending, Sanovas has built a strong IP portfolio for our micro-invasive diagnostics, devices and drug delivery technologies that poise to significantly advance the way pulmonary diseases, such as lung cancer, are detected and treated.

Click here to read the full Sanovas Inc. press release.